November 20, 2026
Source: drugdu
37

On November 19, Tianjin Pharmaceutical (600488) disclosed that China’s National Medical Products Administration had approved its marketing application for dexamethasone active pharmaceutical ingredient (API). Dexamethasone has antiallergic, antipyretic and immunosuppressive properties and is used primarily for allergic and autoimmune inflammatory diseases.
The article lists marketed Chinese dosage forms including single-ingredient dexamethasone tablets and combination products in eye drops, ophthalmic ointments, topical ointments and injections.
Source: http://finance.eastmoney.com/a/202611193935031069.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.